Project Grant HT94252510632

The National Cancer Institute (NCI), under the Federal Grant Program for Cancer Research Manpower (CFDA 93.398), awarded a $135,990 Project Grant to the University of Illinois in Chicago to conduct research on cognition, vascular function, and physical activity in colorectal cancer survivors. The 1.5-year study, beginning January 17, 2025, aims to: (1) compare cognitive processing speed, arterial stiffness, and moderate-to-vigorous physical activity levels between colorectal cancer survivors and...

The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee...

This Project Grant award of $700,049 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a study on the impact of targeted tyrosine kinase inhibitor (TKI) therapies on cancer-related cognitive impairment (CRCI) among patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). The study, led by the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, will recruit 200 patients about to begin TKI treatment for CML or CLL,...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...

The federal Project Grant award R01CA299480, titled "The MIND-BC Study: MIND Diet for Breast Cancer Cognition", is being provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The $713,235 award will fund a randomized controlled trial to evaluate the efficacy of the MIND diet in improving cognitive functioning among breast cancer survivors who have completed adjuvant treatment within the past 3 years and are reporting...

This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $159,183 in funding to The Trustees of the University of Pennsylvania to investigate the role of diet and the enzyme ACSS2 in the metabolic and epigenetic regulation of colorectal cancer. The research aims to determine how the dietary components of fructose and acetate (from fiber metabolism) interact to affect colorectal cancer growth and acetyl-CoA metabolism, as well as identify...

This Project Grant award of $637,596 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to develop and test an intervention to reduce cancer information avoidance and increase colorectal cancer screening. The key products and services being delivered under this 5-year grant, which began on April 4, 2025, include: Conducting a randomized controlled trial to evaluate the effects of a video-based intervention on screening intentions and...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...

The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...